Feature | May 14, 2012

Implantable Defibrillators Fine for Use in Athletes

Yale study shows ICD restrictions for athletes may not be necessary

May 14, 2012 – A study of more than 350 competitive athletes with implantable cardioverter defibrillators (ICDs) from around the world showed for the first time that sports may be safer for this group than has been thought. There were no occurrences of death or injury due to arrhythmia or shock during sports in this group.  Additionally, only 10 percent of the athletes received a shock during competition or practice and of those, most continued to play, as reported at the Heart Rhythm Society (HRS) scientific sessions in Boston.

These results are based on a prospective study, the international ICD Sports Safety Registry.  This study is the first of its kind to offer tangible evidence about the risks of sports activity in athletes with ICDs, empowering physicians to evaluate sports participation on a case-by-case basis. Currently, consensus statements recommend restriction of competitive sports for all athletes with an ICD because of the unknown risks. 

“We did not know if defibrillation would work during sports…The body works differently during sports activity,” said Rachel Lampert, M.D., FHRS, lead author of the study and associate professor of medicine at Yale University School of Medicine.

“The answer to this was zero — there were no injuries,”

There was concern adrenaline and trauma, especially to the ICD leads, might cause the devices to malfunction. The registry followed 372 athletes from around the world for more than 2.5 years. The ages of the patients ranged from 10 to 60. About 70 percent of patients received shocks during the registry, including 30 during sports activity.

“People were getting shocked, but they were appropriate and the defibrillators worked during the sports activities,” Lampert said.

Even though people were shocked during sports, she said most athletes continued with the sport.

“These data suggest that the blanket statement that all vigorous competitive sports be restricted for patients with ICDs may not be necessary. Yet, it by no means suggests that all ICD patients should be playing sports,” said Lampert.  “We believe this continues to reinforce the importance of informed and thoughtful discussions between physicians and patients, and provides new information that will help guide the final decision on whether it is safe for an individual to participate in a competitive sport with an ICD.”

The purpose of an ICD is to convert all episodes of ventricular fibrillation (VF) or ventricular tachycardia (VT) through a defibrillation shock to the heart.  Because the effectiveness of the ICD during the stressful conditions of intense sports was previously unknown, sports have not been recommended.  But, the true risks have also not been known.

The study evaluated the primary endpoints of 1) death or resuscitated arrest or 2) injury during sports due to arrhythmic symptoms and/or shock.  Secondary results that were monitored included system malfunction and incidence of ventricular arrhythmias (VA) requiring multiple shocks for termination.  No primary endpoints occurred and of the secondary results, only ten percent of the athletes were shocked during competition or practice.  Lead malfunction rates were similar to those reported previously for ICD patients leading the authors to conclude “these data do not support competitive sports restriction for all athletes with ICDs.”

The median age for participants in the study was 33, with ages ranging from 10 to 60.  The most common sports were running, basketball and soccer.  Athletes were recruited through physician sites and patient advocacy groups and all were already involved in competitive (n=328) or dangerous (n=44) sports.

For more information: www.HRSonline.org

Related Content

anticoagulants, U.S. market, Technavio, 2020, trends
News | Antiplatelet and Anticoagulation Therapies| May 25, 2016
Technavio’s latest report on the U.S. anticoagulants market provides an analysis on the most important trends expected...
Boston Scientific, FDA, IntelliNav XP ablation catheters, Rhythmia Mapping System

Rhythmia Mapping System image courtesy of Boston Scientific

Technology | Ablation Systems| May 23, 2016
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for two catheters that can be used with...
Watchman, left atrial appendage closure, LAA occluder, LAA. LAAO, laa occluder, left atrial appendage, Watchman

The Boston Scientific Watchman device is currently the only transcatheter LAA occluder cleared for use in the United States.

Feature | Left Atrial Appendage (LAA) Occluders| May 20, 2016 | Dave Fornell
Atrial fibrillation (AF) affects nearly 6 million Americans and the condition puts them at significantly greater risk
News | Atrial Fibrillation| May 19, 2016
Physician-researchers in the College of Medicine at the University of Cincinnati have developed a computerized decision...
Johns Hopkins, virtual heart modeling tool, VARP, arrhythmias, implanted defibrillator

Examples of how the computer model would classify one patient at high risk for heart arrhythmia and another at low risk. Image courtesy of Royc Faddis/Johns Hopkins University.

News | Cardiac Diagnostics| May 17, 2016
May 17, 2016 — An interdisciplinary Johns Hopkins University team has developed a...
News | Ablation Systems| May 11, 2016
Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are...
Medtronic, FDA approval, MR-conditional CRT-Ds, defibrillators, Amplia, Compia
Technology | Cardiac Resynchronization Therapy Devices (CRT)| May 11, 2016
Medtronic plc recently announced it received U.S. Food and Drug Administration (FDA) approval for the first and only...
Imricor, Vision-MR ablation catheter, clinical study, MRI guidance
News | Ablation Systems| May 10, 2016
Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR...
Medtronic, Micra transcatheter pacing system, study data, HRS 2016
News | Pacemakers| May 10, 2016
Medtronic plc announced clinical results highlighting the strong safety and performance profile of the miniaturized...
LivaNova, SonR hemodynamic sensor, CRT, heart failure, RESPOND CRT trial, HRS 2016
News | Cardiac Resynchronization Therapy Devices (CRT)| May 10, 2016
The first-ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in...
Overlay Init